Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Innovent Starts Phase II Trial of CTLA-4 mAb for Cervical Cancer

publication date: Dec 11, 2020

Suzhou Innovent Bio has dosed the first patient in a Phase II trial of its CTLA-4 mAb in combination with Tyvyt® (sintilimab injection) as a second-line treatment for advanced cervical cancer. The randomized, double-blind trial will compare the efficacy and safety of the combination against Tyvyt, an anti-PD-1 drug, by itself. Innovent points out that the long-term survival rate of Stage IVb cervical cancer is very low, and patients who fail platinum-based chemotherapy have few options. No CTLA-4 drug has been approved for China use. More details....

Stock Symbol: (HK: 01801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.